ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach

Targeting GI Diseases

 
• By Ayisha Sharma
  
Emerging Company Profile: ThirtyFiveBio
The Firm Will Likely Work On Colorectal Cancer As A First Indication • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Emerging Company Profiles

More from Start-Ups & SMEs